- Home
- AVTX vs CUE Comparison
AVTX vs CUE Comparison
Compare AVTX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | CUE |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.6M | 233.5M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AVTX | CUE |
|---|---|---|
| Price | $15.06 | $25.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $40.57 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 953.5K | 351.9K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,813,137.00 | $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | 195.75 |
| 52 Week Low | $12.41 | $0.17 |
| 52 Week High | $24.27 | $45.50 |
Technical Indicators
Market Signals| Indicator | AVTX | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 32.60 | 41.16 |
| Support Level | $12.98 | $23.51 |
| Resistance Level | $15.27 | $33.11 |
| Average True Range (ATR) | 0.93 | 5.01 |
| MACD | -0.16 | -0.64 |
| Stochastic Oscillator | 11.81 | 6.50 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.